Pds Biotechnology CORP 8-K filings

PDS Biotechnology is shifting its clinical focus to a triple combination therapy for advanced head and neck cancer after observing strong survival and response rates in a Phase 2 trial.

PDS Biotechnology announced the publication of preclinical research and the grant of a U.S. patent, strengthening its Infectimune infectious disease vaccine platform.

PDS Biotechnology Corporation announced the retirement of its Chief Medical Officer, Lauren V. Wood, M.D., and the appointment of Kirk V. Shepard, M.D., as her successor, along with an amendment to its stock option plan.